Guizhou Xinbang Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Guizhou Xinbang Pharmaceutical has been growing earnings at an average annual rate of 59.3%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 0.2% per year. Guizhou Xinbang Pharmaceutical's return on equity is 5.1%, and it has net margins of 4.6%.
Key information
59.3%
Earnings growth rate
58.7%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 0.2% |
Return on equity | 5.1% |
Net Margin | 4.6% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Guizhou Xinbang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 6,438 | 293 | 784 | 5 |
31 Dec 23 | 6,461 | 287 | 803 | 5 |
30 Sep 23 | 6,487 | 230 | 816 | 3 |
30 Jun 23 | 6,463 | 249 | 826 | 3 |
31 Mar 23 | 6,377 | 204 | 859 | 2 |
01 Jan 23 | 6,350 | 224 | 855 | 1 |
30 Sep 22 | 6,435 | 304 | 813 | 2 |
30 Jun 22 | 6,517 | 252 | 827 | 1 |
31 Mar 22 | 6,590 | 274 | 802 | 2 |
01 Jan 22 | 6,472 | 273 | 793 | 2 |
30 Sep 21 | 6,289 | 260 | 822 | 1 |
30 Jun 21 | 6,241 | 290 | 806 | 2 |
31 Mar 21 | 6,060 | 259 | 787 | 3 |
31 Dec 20 | 5,846 | 174 | 813 | 11 |
30 Sep 20 | 5,916 | 159 | 829 | 23 |
30 Jun 20 | 6,080 | 151 | 872 | 30 |
31 Mar 20 | 6,339 | 161 | 932 | 32 |
31 Dec 19 | 6,655 | 236 | 925 | 37 |
30 Sep 19 | 6,573 | -1,360 | 963 | 38 |
30 Jun 19 | 6,584 | -1,371 | 926 | 36 |
31 Mar 19 | 6,630 | -1,308 | 924 | 41 |
31 Dec 18 | 6,580 | -1,297 | 918 | 37 |
30 Sep 18 | 6,651 | 337 | 834 | 30 |
30 Jun 18 | 6,527 | 368 | 815 | 47 |
31 Mar 18 | 6,160 | 341 | 731 | 38 |
31 Dec 17 | 6,002 | 319 | 708 | 30 |
30 Sep 17 | 5,800 | 293 | 800 | 22 |
30 Jun 17 | 5,437 | 263 | 792 | 0 |
31 Mar 17 | 5,350 | 255 | 793 | 0 |
31 Dec 16 | 5,157 | 246 | 756 | 0 |
30 Sep 16 | 5,044 | 243 | 668 | 0 |
30 Jun 16 | 4,864 | 223 | 624 | 0 |
31 Mar 16 | 4,488 | 185 | 593 | 0 |
31 Dec 15 | 4,180 | 174 | 540 | 0 |
30 Sep 15 | 3,788 | 189 | 462 | 0 |
30 Jun 15 | 3,477 | 180 | 440 | 0 |
31 Mar 15 | 3,217 | 172 | 420 | 0 |
31 Dec 14 | 2,476 | 145 | 389 | 0 |
30 Sep 14 | 1,732 | 100 | 365 | 0 |
30 Jun 14 | 1,113 | 69 | 343 | 0 |
31 Mar 14 | 572 | 39 | 301 | 0 |
31 Dec 13 | 569 | 40 | 301 | 0 |
30 Sep 13 | 529 | 42 | 275 | 0 |
30 Jun 13 | 493 | 42 | 254 | 0 |
Quality Earnings: 002390 has high quality earnings.
Growing Profit Margin: 002390's current net profit margins (4.6%) are higher than last year (3.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002390 has become profitable over the past 5 years, growing earnings by 59.3% per year.
Accelerating Growth: 002390's earnings growth over the past year (43.8%) is below its 5-year average (59.3% per year).
Earnings vs Industry: 002390 earnings growth over the past year (43.8%) exceeded the Pharmaceuticals industry -0.9%.
Return on Equity
High ROE: 002390's Return on Equity (5.1%) is considered low.